Oral Antiviral Blocks Measles Spread in Ferrets
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- GHP-88310, an experimental oral antiviral developed by Georgia State University researchers, blocked both airborne and direct-contact transmission of canine distemper virus — a measles-like pathogen — in ferrets when given shortly before or after exposure.
- Richard Plemper, a Regents' Professor and director of the Center for Translational Antiviral Research, and first author Carolin Lieber published the findings in Nature Microbiology, describing the drug as a broad-spectrum viral polymerase inhibitor.
- GHP-88310 also shortened illness duration and reduced the contagious window when given therapeutically to already-infected ferrets, with Plemper calling the airborne-transmission result 'unprecedented for a viral polymerase inhibitor.'
- The study separately tested ferrets sharing airspace without touching and ferrets in direct contact, modeling the kinds of spread that occur in classrooms and households.
- Measles has reemerged in the US since 2025, causing thousands of infections, hundreds of hospitalizations, and three confirmed deaths, with major outbreaks in Canada and Mexico raising concerns about North America's elimination status.
- The research team is now preparing GHP-88310 for formal clinical trials, with funding from the National Institute of Allergy and Infectious Diseases (NIAID).
Why it matters: If the ferret findings translate to humans, GHP-88310 would become the first oral antiviral that blocks measles transmission rather than just easing symptoms, giving outbreak responders a deployable tool alongside ring vaccination at a moment when North American outbreaks have already killed at least three in the US and put elimination status at risk.
